ArticleResearch and practice in thrombosis and haemostasis2017
Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study.
Article in Research and practice in thrombosis and haemostasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005504 (Longitudinal Investigation of Thromboembolism Etiology), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Investigation of Thromboembolism Etiology
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- The Role of Galectin-3 in Atherosclerosis and Its Cardiovascular Complications: An Update.Journal of lipid and atherosclerosis · 2026Review
- Discovery of crucial cytokines associated with deep vein thrombus formation by protein array analysis.BMC cardiovascular disorders · 2024Article
- Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2024Article
- Galectin-3-binding protein and future venous thromboembolism.Research and practice in thrombosis and haemostasis · 2024Article
- A phenome-wide approach to identify causal risk factors for deep vein thrombosis.BMC medical genomics · 2023Article
- Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2022Article
- Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics.Journal of medical biochemistry · 2021Article
- Interaction between Galectin-3 and Integrins Mediates Cell-Matrix Adhesion in Endothelial Cells and Mesenchymal Stem Cells.International journal of molecular sciences · 2021Article
- Inter-Relationship between Platelet-Derived Microparticles and Oxidative Stress in Patients with Venous Thromboembolism.Antioxidants (Basel, Switzerland) · 2020Article
- Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics.Journal of thrombosis and haemostasis : JTH · 2018Article
- Galectin-3 in venous thrombosis: A possible new target for improved patient care.Research and practice in thrombosis and haemostasis · 2018Article
- Galectin-3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort.European journal of neurology · 2017Article
- Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study.Research and practice in thrombosis and haemostasis · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThe inflammatory biomarker galectin-3 contributes to pathologic conditions such as heart failure and stimulates murine thrombogenesis. Its association with venous thromboembolism (VTE) has been sparsely studied.
objectivesTo assess the prospective association of plasma galectin-3 and the
methodsWe measured plasma galectin-3 in 9,916 participants in the Atherosclerosis Risk in Communities (ARIC) study cohort in 1996 - 1998 and identified VTEs through 2013. Using Cox regression, we estimated the hazard ratio associating galectin-3 with incident VTE over a median of 13.9 years. Replication was sought in the Cardiovascular Health Study (CHS).
resultsARIC included 21.8% blacks and 56.2% females with mean baseline age of 62.7 years. The incidence rate of VTE (n=389 events) increased across quintiles of galectin-3, with hazard ratios (95% CI) of 1 (reference), 1.13 (0.80 - 1.61), 1.00 (0.70 - 1.43), 1.36 (0.96 - 1.91), and 1.55 (1.09 - 2.19) (p-trend = 0.005), adjusted for age, sex, race, body mass index, diabetes status, and renal function. Results did not replicate in the CHS (124 VTE), but meta-analysis of both studies yielded a pooled hazard ratio (95% CI) for 1 SD increment in log galectin-3 of 1.10 (1.00 - 1.22). In ARIC, the C allele of rs4644 in the
conclusionGalectin-3 levels were associated positively with VTE incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.